The cardiovascular risks seen with a higher-than-approved dose of Pfizer Inc.'s Janus kinase (JAK) inhibitor Xeljanz in a long-term rheumatoid arthritis study required by the US FDA have cast a shadow over the drug's other indications and for the class overall.
Xeljanz (tofacitinib) has been approved by the FDA since 2012 at the dose of 5 mg twice daily for moderate-to-severe...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
